<?xml version="1.0" encoding="UTF-8"?>
<p id="para0007">MetS is defined as a cluster of risk factors such as raised blood pressure, atherogenic dyslipidemia, raised fasting glucose, and central obesity, related to the development of CVD and T2DM (
 <xref rid="bib0004" ref-type="bibr">Alberti et al., 2009</xref>). Since the World Health Organization (WHO) reported the first formalized definition of the MetS, the diagnostic criteria have been sequentially developed by several public health organizations (
 <xref rid="bib0041" ref-type="bibr">Engin, 2017</xref>). Nowadays, the most recognized criterion for the clinical diagnosis of MetS (
 <xref rid="bib0004" ref-type="bibr">Alberti et al., 2009</xref>) is based on identifying at least three of the following risk factors: (1) elevated waist circumference (population and country-specific definitions determined by local organizations); (2) triglycerides (TG) ≥ 150 mg/Dl (&lt;1.0 mmol/L) or on drug treatment for elevated triglycerides; (3) high-density lipoproteins-cholesterol (HDL-C) &lt;40 mg/dL (&lt;1.0 mmol/L) in men or &lt;50 mg/dL (&lt;1.3 mmol/L) in women or on drug treatment for reduced HDL-C; (4) blood pressure ≥130/85  mmHg or on antihypertensive medication treatment, and/or a history of hypertension; and (5) fasting glucose &gt;100 mg/dL (&gt;5.6 mmol/L) or on drug treatment for elevated glucose.
</p>
